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2 BACKGROUND/OBJECTIVES: Short chain fatty acids (SCFA), produced by microbiome 
3 fermentation of carbohydrates, have been linked to a reduction in appetite, body weight and 
4 adiposity. However, determining the contribution of central and peripheral mechanisms to 
5 these effects has not been possible. 
6 SUBJECTS/METHODS: C57BL6 mice fed with either normal or high fat diet (NFD and HFD, 
7 respectively) were treated with nanoparticle delivered acetate and the effects on metabolism 
8 were investigated.
9 RESULTS: In the liver, acetate decreased lipid accumulation and improved hepatic function, 
10 as well as increasing mitochondrial efficiency. In white adipose tissue, it inhibited lipolysis 
11 and induced “browning”, increasing thermogenic capacity which led to a reduction in body 
12 adiposity. 
13 CONCLUSIONS: This study provides novel insights into the peripheral mechanism of action 




18 Obesity, arising from an imbalance between energy intake and energy expenditure, leads to 
19 a number of metabolic dysfunctions, including excess triglyceride synthesis and hepatic lipid 
20 accumulation (1). There is increasing evidence linking fermentable carbohydrates (FC) to the 
21 management of appetite regulation and negative energy balance in healthy and obese 
22 subjects (2-4). Several studies have shown that dietary supplementation of FC results in 
23 appetite suppression, reduced body adiposity, lower lipid accumulation in liver cells, as well 
24 as increased expression of anorexigenic gut hormones (3, 5-8). The consumption of FC 
25 results in the formation of SCFA mainly acetate, propionate and butyrate in the colon by 
26 microbiota. Butyrate is largely utilized as a substrate for colonocytes; propionate is taken up 
27 by the gut and mostly metabolized by the liver whereas acetate enters the peripheral 
31 circulation (9). It has been suggested that increased production of SCFAs may play an 
2 important role in both satiety and adipose tissue (AT) remodeling (10). 
3 Acetate is the main SCFA found in circulation and therefore the prime candidate to induce 
4 significant metabolic modulation in peripheral tissues. There is however conflicting evidence 
5 regarding the mechanism of action of acetate on lipid metabolism which may arise from its 
6 short half-life combined with the non-targeted nature of oral and peripheral administration. 
7 While some studies showed that administration of SCFAs acetate and propionate, inhibit 
8 lipolysis (11, 12), others have shown that acetate decreased fat accumulation through 
9 modification of either fatty acid oxidation (13) or fatty acid synthesis and AMP-activated 
10 protein kinase (AMPK) activity (14, 15) Recently, we have shown that acetate plays an 
11 important role in appetite suppression (16). Although we have found evidence to support a 
12 central mechanism for the mode of action of acetate, less is known regarding potential 
13 peripheral mechanisms. 
14 In order to assess the peripheral action of acetate, herein we utilize a novel nanoparticle 
15 delivery method, whereby acetate is passively targeted to the periphery.  Using this method 
16 we investigated the effects of acetate on liver lipid accumulation, inflammation and 
17 mitochondrial metabolism. Our findings suggest that the positive effects of acetate on liver 
18 lipid accumulation are as a result of mitochondrial modifications in both the liver and 
19 subcutaneous adipose tissue (SAT), leading to “browning” of SAT and an overall 
20 improvement in metabolism and body composition in the absence of changes in calorie 
21 intake or physical activity. 
22
23 MATERIALS AND METHODS
24 Experimental Animals
25 All in vivo experiments were carried out in compliance with the Animals (Scientific 
26 Procedure) Act 1986. Mice were supplied by Harlan, UK and housed 4 per cage, in a 
27 temperature controlled room at approximately 21-23°C with alternating 12h periods of light 
41 and dark (light: 7:00-19:00) in filter-topped cages with ad libitum access to water. NFD was 
2 the RM3 diet supplemented by Special Diet Services (Essex, UK). 60% of the caloric content 
3 of the HFD was fat (EF D12402; Special Diet Services).
4
5 Chronic Liposome encapsulated acetate (LITA) Nanoparticle Administration to C57BL/6 
6 Mice Placed on a HFD or NFD
7 Male adult C57BL/6 mice were placed on either a HFD (n=48) or NFD (n=48) for 6 weeks. 
8 Within each dietary group mice received an intraperitoneal (i.p.) injection of either LITA 
9 nanoparticle (n=24) or control (HEPES) (n=24) three times per week. Whole body 1H 
10 Magnetic resonance spectroscopy (MRS) and liver 1H MRS were performed prior to dietary 
11 intervention and after 4 weeks of the start of the study to calculate whole body adiposity and 
12 intrahepatocellular lipid (IHCL) content, respectively. At the start of week 5, a fasted glucose 
13 tolerance test (GTT) was performed, (n=10-12) or animals went into Comprehensive Lab 
14 Animal Monitoring System (CLAMS, Columbus Instruments, USA) (n=8). After week 6 
15 animals were euthanized; blood samples and organs, including the liver, epididymal, 
16 mesenteric and subcutaneous fat depots were collected and stored at -80°C for 
17 measurement of enzymes, markers and gene expression analysis. The details of all 
18 procedures are provided in the Supplementary Information. 
19
20 Cell Culture
21 THLE-2 cells (ATCC® CRL-2706TM) which are derived from normal human liver cells and 
22 transformed with SV40 large T antigen were purchased from ATCC and grown in BEBM 
23 medium supplemented with BEGM bullet kit (Lonza, Switzerland) at 370C with 5% CO2 as 
24 per ATCC’s instructions. A549 Parent (wild type) and rho0 (lacking mitochondrial DNA) lung 
25 cancer cells were grown in DMEM supplemented with uridine only for rho0 at 370C with 5% 
26 CO2 as described in (17). Mitochondrial function of all cell types was assessed using a XF24 




3 All statistical analyses were performed using GraphPad Prism (GraphPad Software, USA). 
4 Data are presented as means ± standard deviation (SD) except where stated as mean ± 
5 standard error of mean (SEM). Statistical significance was calculated with Student’s t test or 
6 repeated measures ANOVA analysis where appropriate. Significance was accepted at the 
7 level of *=p<0.05, **=p< 0.01, ***=p<0.001.
8
9 RESULTS
10 Development of Nanoparticle Delivery System for Acetate
11 LITA (Supplementary Figure S1a) nanoparticles were prepared from lipids by thin film 
12 hydration method, then employed for the functional delivery of acetate to the main organs in 
13 the periphery following i.p. administration (16). To show that acetate is encapsulated in the 
14 liposomes we employed the affinity of albumin to bind ions and the fact that it is NMR 
15 “invisible”. When acetate binds to albumin it becomes “invisible” to NMR (Supplementary 
16 Figure S1 b and c) but when acetate is encapsulated in the liposomes albumin cannot bind 
17 to it and the acetate peak is still visible (Supplementary Figure S1 d and e). The 
18 concentration of acetate was similar to physiological levels; in 200µl of LITA about 52.9μg 
19 (4.41mM) and the size of the liposomes were 102.3 ± 7.5nm and 95.9 ± 9.0nm for LITA and 
20 control liposomes respectively (p=0.6). 100nm is suggested as optimal size to create stable 
21 liposomes (18, 19).
22 Biodistribution to the liver, heart, muscle, spleen and lung was confirmed by histological 
23 analysis (making use of fluorescence tags, LITA-Rhd) at 2h post administration 
24 (Supplementary Figure S1f-j). Extended biodistribution at 24 and 48h post administration 
25 was assessed by magnetic resonance imaging (MRI), using a positive lipid-based contrast 
26 agents (LITA-Gd) (20). Increased uptake of LITA-Gd in liver was confirmed by the expected 
61 reduction in T1 value (Supplementary Figure S1k). No change in brain T1 was observed 
2 (Supplementary Figure S1l). Overall these studies confirmed that only peripheral tissues 
3 were reached by the LITA nanoparticle. This is typical for nanoparticles of this type, 
4 confirming that LITA nanoparticles do not enter the brain. Therefore results obtained in this 
5 study would be independent of any potential appetite suppressing effect by acetate.
6
7 Acetate Reduces Whole Body and Ectopic Lipid Accumulation with No Reduction in Food 
8 Intake or Weight Gain
9 In order to assess the effects of acetate on overall metabolism, lean 8-week-old C57Bl/6 
10 mice were put on NFD or HFD and were administered i.p. with Control or LITA nanoparticles 
11 3 times per week for 6 weeks. Acetate administration in LITA nanoparticles reduced whole 
12 body adiposity significantly in HFD fed mice (p<0.05) with similar trend in NFD fed mice 
13 (p<0.08) (Figure 1a and 1b). No change was observed in the daily food intake of both 
14 groups, even so the NFD group showed an overall weight gain with LITA treatment 
15 (Supplementary Figure S2a-d). Furthermore, lean mass was significantly increased in the 
16 HFD fed group with LITA treatment (p<0.05) with a similar trend was observed in the NFD 
17 fed group (p=0.07, Figure 1c and 1d). Importantly, LITA treatment in both groups led to a 
18 reduced accumulation of IHCL in both groups (p<0.05, Figure 1e and 1f) compared with 
19 control nanoparticle treatment. Similar reductions were observed in whole body adiposity 
20 (p<0.05) and IHCL (p<0.001) with LITA treatment under a more robust model of obesity, 
21 where mice were fed with HFD for 5 weeks prior to treatment with LITA, (Supplementary 
22 Figure S2e and f) again these changes were independent of changes in food intake or 
23 weight gain (data not shown). Pancreatic triglyceride (TG) levels also exhibited a trend 
24 towards reduction in both groups (Supplementary Figure S2g). No morphological 
25 abnormalities were observed in either group in the liver of LITA or control nanoparticle 
26 treated mice (Supplementary Figure S2h) nor were there significant changes observed in 
71 weight of the liver or of pancreas (Supplementary Figure S2i and j), as well as the size or 
2 volume of adipocytes from SAT (Supplementary Figure S3a-e).
3 Acetate improves liver function 
4 LITA treatment resulted in a reduction in aspartate aminotransferase (AST) and alkaline 
5 phosphatase (ALP) serum levels in the HFD group suggesting an improvement in liver 
6 function (p<0.05, Figure 2a). Similarly, there was a reduction in serum interleukin-6 (IL-6) 
7 and tumor necrosis factor-α (TNF-α) concentrations in HFD fed mice treated with LITA, 
8 though this did not reach significance (p<0.07, Figure 2b). This was associated with a 
9 reduction in TNF-α expression in both the liver (p<0.01) and SAT (p<0.001) (Figure 2c). No 
10 change was observed in liver function enzymes of NFD mice treated with LITA but a 
11 significantly lower serum concentration of TNF-α (p<0.01) and reduced expression of TNF-α 
12 in the liver (p<0.05) was observed (Figure 2d and 2e). These changes are significant since 
13 pro-inflammatory cytokines such as TNF-α and IL-6 are believed to trigger inflammation in 
14 the liver following lipid accumulation, leading to liver fibrosis (21). No changes were 
15 observed in monocyte chemoattractant protein-1 (MCP-1) or resistin in both cohorts (Figure 
16 2f and 2g)
17
18 Glucose metabolism is altered by acetate 
19 No change was observed in the recovery of blood glucose to baseline level after GTT in 
20 NFD (Figure 3a and 3b) or HFD (Figure 3c and 3d). In NFD cohort, homeostatic model 
21 assessment of insulin resistance (HOMA-IR) was significantly reduced with acetate 
22 treatment (Figure 3e and 3g). In HFD cohort, the fasted level of glucose dropped less, with 
23 no change in fasted insulin and fed insulin levels were lower (p<0.05) with no change in fed 
24 glucose (Figure 3f and 3g). The gene expression of glucose transporter 2 (GLUT2) in HFD 
25 cohort, was significantly reduced with LITA treatment (p<0.01, Fig. 3h). Serum glucagon 
26 levels showed a significant increase with LITA administration compared to control in HFD fed 
27 mice (p<0.05, Figure 2g), possibly due to reduced insulin levels. 
28
81 Acetate reduces AT lipolysis, circulating free fatty acid (FFA) levels and de-novo lipogenesis 
2 in liver
3 In HFD fed mice, the gene expression of adipose tissue triglyceride lipase (ATGL), which 
4 breaks down TG into diacylglycerols and FFAs (22) was reduced with LITA (Figure 4a),  
5 correlating with reduced circulating levels of serum FFAs (p<0.05, Figure 4b). Similarly, 
6 mRNA expression of genes in liver involved in de-novo lipogenesis, namely sterol regulatory 
7 element-binding protein 1 (SREBP1), Fatty acid synthase (FASN) and Acetyl-CoA 
8 carboxylase (ACC), were significantly reduced following LITA treatment (p<0.01, Figure 4c). 
9 These reductions in circulating serum FFAs, due to reduced SAT-based lipolysis, together 
10 with reductions in de-novo lipogenesis could certainly offer explanation for the observed 
11 reduction in IHCL with LITA treatment. These effects appear to be balanced by LITA 
12 treatment induced reductions in fatty acid oxidation and VLDL export compared to control, as 
13 reflected by downregulation in expression of fatty acid oxidation genes carnitine 
14 palmitoyltransferase I (CPT1, p<0.01) and acyl-CoA oxidase 1 (ACOX, p<0.05) and VLDL 
15 synthesis (p<0.001). These latter data are in line with reduced FFAs reaching the liver.
16
17 Acetate improves liver mitochondrial function and increases ATP production 
18 Impaired mitochondrial metabolism is an underlining cause for a number of diseases 
19 including fatty liver (23). Initially, liver mitochondria were assessed using transmission 
20 electron microscopy (TEM). No change was observed in the number of mitochondria (Figure 
21 5a and 5b) while genes involved in the mitochondrial biogenesis remained unaffected 
22 (Figure 5e). However, a trend towards increasing numbers of cristae per mitochondria was 
23 observed (p<0.07, Figure 5c and 5d). As cristae are the sites for electron transport chain 
24 (ETC), protein expression of these complexes was investigated. Significant increases in the 
25 expression of complexes III, IV and V were detected (p<0.05, p<0.01 and p<0.001, 
26 respectively, Figure 5f and 5h). Moreover there was a significant reduction in expression 
27 levels of uncoupling protein 2 (UCP2, p<0.05, Figure 5E), suggesting a less “leaky” 
28 mitochondrial membrane, providing more electrons for the ETC and increased ATP 
91 production. In order to further assess the potential effect of acetate on ATP production, 
2 immortal non-cancerous hepatocytes (THLE-2, an in vitro model for normal liver cells) were 
3 treated with acetate and oxygen consumption rate (OCR) was monitored using a XF-
4 analyzer. Basal respiration and ATP production were significantly increased by acetate. 
5 (Figure 5g). 
6
7 Acetate increases thermogenic capacity through “browning” of white adipose tissue (WAT)
8 HFD and NFD fed mice treated with LITA or its control counterpart underwent physiological 
9 analysis by CLAMS. Acetate administration by LITA nanoparticle increased heat production 
10 in both HFD (p<0.01, Figure 6a and 6b) and NFD (p<0.05, Figure 6c and 6d) fed mice. 
11 Recently it has been shown that WAT depots can be “browned” by activators such as cold 
12 (24-27). ‘Beige’ or ‘brite’ adipocytes have more abundant mitochondria compared to white 
13 adipocytes, thus increasing thermogenic potential (28). Since we observed increased 
14 thermogenic output in the LITA treated animals, gene expression of UCP1 in SAT was 
15 investigated. In the HFD cohort, UCP1 expression was significantly increased (p<0.001, 
16 Figure 6e). We then went on to assess peroxisome proliferator activated receptor gamma 
17 coactivator 1 alpha (PGC1α) and PR domain containing 16 (PRDM16) to confirm the 
18 possibility of “browning” of WAT as both are involved in the differentiation of brown-like 
19 adipocytes (25, 29). PRDM16 was significantly increased (p<0.001), while PGC1α showed a 
20 similar trend (Figure 6E). In the NFD cohort a significant increase in PRDM16 (p<0.001) 
21 expression was also observed, while UCP1 and PGC1α expressions remained unchanged 
22 (Figure 6f). These changes occurred independent of changes in size or UCP1 expression of 
23 brown adipose tissue (BAT, the AT depot behind the neck of mice), the main site for heat 
24 production (Figure 6g and 6h). In both cohorts VO2 and VCO2 trended to be higher but did 
25 not reach significance and physical activity was unaffected by LITA treatment 




1 Positive effects of acetate are lost in the presence of dysfunctional mitochondria
2 Rho0 cells, derived from A549 lung cancer cells, lack mitochondrial DNA (17), and are 
3 deficient in proteins of respiratory complexes I, III, IV and V (30) (Supplementary Figure 
4 S6a). Rho0 cells and wild type A549 cells (parent) were treated with 1mM acetate leading to 
5 increased ATP-linked respiration in ‘parent’ cells (p=0.06) whereas this effect was absent in 
6 Rho0 cells (p<0.4, Supplementary Figure S6b and c). In order to confirm in vivo that the 
7 beneficial effects of acetate on adiposity and inflammation was mediated by mitochondria, a 
8 group of mice were put on methionine choline deficient diet (MCD) and treated with LITA 
9 versus control nanoparticles. Mice on MCD have been previously shown to have impaired 
10 mitochondrial function and increased liver inflammation (31). No reversal in liver fat 
11 accumulation or body adiposity was observed following LITA treatment (Supplementary 
12 Figure S6d). In addition serum inflammatory markers remained unchanged by LITA 
13 treatment (Supplementary Figure S6e) confirming that acetate requires functional 





19 In this study we make novel mechanistic insights into the peripheral effects of the SCFA 
20 acetate, following its delivery by a nanoparticle mediated system. The beneficial peripheral 
21 phenotypic effects of acetate are clearly independent of its effect on brain, where it is also 
22 known to be active (16). Our results reveal for the first time that acetate stimulates a number 
23 of autonomous mechanisms in different peripheral tissues. In the liver it reduces fat 
24 deposition through a reduction in circulating FFAs and de-novo lipogenesis and an increase 
25 in mitochondrial efficiency, while in adipose tissue it induces “browning”, leading to a 
26 contraction in body adiposity.
27 Peripheral administration (oral/i.p.) of acetate has been previously shown to result in non-
28 targeted uptake, rapid clearance from the circulation and reduced pH (32). Lipid based 
11
1 nanoparticles (LNP) such as LITA can be used to target drugs to tissues (33) and have been 
2 employed in our lab to mediate functional siRNA delivery (34), as well as MRI contrast-
3 agents, to tumors (18, 20). By adopting this methodology we passively target the liposomes 
4 to peripheral tissues and increase the bioavailability of acetate. This enables in vivo studies 
5 of the mechanism underlying the action of individual SCFA (separately or in combination) to 
6 be undertaken in a more controlled manner. This is important as recent work suggest that 
7 propionate and butyrate have very distinctive metabolic effects (35). Furthermore, our 
8 methodology allows for a separation of peripheral and central effects of acetate. 
9 Our data herein shows that acetate reduces whole body fat without a decrease in caloric 
10 intake or weight gain. Previously, Yamashita et al have reported reduced food intake and 
11 weight in mice that received acetate orally (14) however, like others, their experimental 
12 design made it impossible to disassociate central from peripheral effects. Indeed, we 
13 recently demonstrated the central mechanism underpinning the appetite suppressing effect 
14 of acetate, and how this effect is lost when acetate is encapsulated in liposomes (16). Thus, 
15 the use of a LNP delivery system in our study enabled us to investigate the effect of acetate 
16 independent of its appetite suppressing action, which partly explain the lack of weight 
17 change reported by others (13, 14). Furthermore, the decrease in adiposity observed in our 
18 study was accompanied by an increase in lean mass, which would in turn balance changes 
19 in overall weight.  
20 We have also observed that acetate treatment reduces ectopic fat accumulation firstly by 
21 reducing lipolysis (11) through a reduction in expression of ATGL in SAT (22), which 
22 correlates with the observed reduction in serum FFA concentration. Reduced circulating 
23 FFAs then ameliorate hepatic exposure resulting in reduced TG synthesis and deposition in 
24 liver. This finding is supported by a recent report that FFA is the main mechanism 
25 responsible for TG synthesis in the liver (36).  Furthermore, we also see a reduction in 
26 insulin which is known to regulate de-novo lipogenesis in the liver through its action on 
27 SREBP1 (37). Suppression of SREBP1 expression and lowering glucose uptake by the liver, 
28 shown by reduced GLUT2 expression, is known to reduce de-novo lipogenesis (38). 
12
1 Together with SREBP1, the expression of downstream genes FASN and ACC was 
2 concomitantly reduced. Recent studies have suggested that acetate in the liver is converted 
3 into acetyl-coA in the cytoplasm through ACSS2 and synthesized to long chain fatty acids 
4 (39). However, in our study we show that chronic treatment with acetate suppresses the 
5 expression of ACSS2, together with lipid synthesis and it increases the expression of 
6 oxidative phosphorylation (OXPHOS) proteins suggesting improved mitochondrial 
7 metabolism.
8 Glucose metabolism was also affected by acetate treatment. Reduced insulin and 
9 maintained glucose concentrations in fed state suggest acetate improves insulin sensitivity. 
10 In the fasted state, the drop in blood glucose levels in mice treated with LITA nanoparticles 
11 was not as pronounced as in mice treated with control nanoparticles. This is contrary to 
12 findings of Yamashita et al who reported a reduction in fasting glucose with acetate 
13 treatment, although their use of a  diabetic rat model may account for these differences (14). 
14 In addition, the observed reduction in expression of GLUT2 following LITA treatment, 
15 together with reduced serum insulin and a less enhanced drop in blood glucose in the fasted 
16 state, are consistent with changes in the liver fuel source away from glucose. This is in 
17 agreement with the Randle hypothesis (40) that links fatty acids to inhibition of glucose 
18 oxidation.
19 Mitochondria, which are at the center of fatty acid metabolism and oxidative phosphorylation, 
20 play a key role in hepatocyte function (23). Mitochondrial dysfunction is also closely linked to 
21 the pathogenesis of non-alcoholic fatty liver disease (NAFLD) (41). Furthermore, increased 
22 UCP2 expression has been associated with non-alcoholic steatohepatitis (NASH) 
23 development (42) and lipid accumulation reduces the efficiency of OXPHOS in liver (43). In 
24 our study we have observed reduced UCP2 expression in LITA treated mice together with 
25 increased protein expression of OXPHOS complexes. In immortal THLE-2 cells ATP-linked 
26 respiration is increased with acetate treatment. Furthermore, when mitochondrial function is 
27 impaired (in Rho0 cells, by deletion of mitochondrial DNA and in vivo, by feeding a MCD) 
28 ATP production and liver fat accumulation remain unaffected by LITA treatment. This strong 
13
1 evidence that enhancement in mitochondrial function is pivotal to the prevention of NAFLD 
2 by acetate. Although in vitro, lung cancer cells were used instead of liver cells, A549 cells 
3 still carry out beta-oxidation (44) which makes them a good model for investigating the effect 
4 of acetate on mitochondria function.
5 Mitochondrial modulations in adipose tissue may also explain how acetate reduces whole 
6 body adiposity without appetite suppression. Acetate treatment causes increased 
7 thermogenic capacity in mice, independent of BAT, through the process of “browning” of 
8 WAT. It has been recently shown that heat dissipation by browning of WAT plays a greater 
9 role in the management of obesity than the BAT itself (45, 46). This is in line with reports that 
10 mice lacking the mitochondrial acetyl-CoA synthatase 1 (ACSS1) are hypothermic when 
11 fasted (47). However, it is not clear whether the “browning process” in this study is a direct 
12 effect of acetate or due to the effects of reduced overall adiposity, which may in turn lead to 
13 “browning” of WAT (48). Similarly, the observed increase in lean mass may contribute to 
14 overall energy expenditure and reduce AT content (49). Moreover, inhibition of 
15 gluconeogenesis has been recently linked with increased energy expenditure (50). Since 
16 acetate appears to reduce liver glucose production, this should also be investigated as a 
17 potential route of action.
18 The overall benefits of acetate on the liver are strongly supported by reduced expression of 
19 TNF-α and lower serum TNF-α and IL6, suggesting less basal inflammation (51, 52). In 
20 addition, the reduction in serum AST and ALP levels, which are normally associated with 
21 NAFLD (53), are a strong indicator of hepatocellular damage. Although these changes were 
22 observed at an early stage of high fat feeding, they do suggest that LITA treatment may help 
23 to prevent the onset of NAFLD. In fact, when mice were fed with HFD for 5 weeks prior to 
24 treatment with LITA, significant reduction in IHCL level was observed. Furthermore, reduced 
25 levels of inflammation, serum insulin, serum FFAs and liver fat are all implicated in 
26 minimizing progression towards tumorigenesis (54, 55). The effect of acetate on 
27 tumorigenesis should also be investigated.
14
1 In conclusion, our study demonstrates significant peripheral effects of acetate on lipid 
2 metabolism, independent of its central action. Acetate administration via LNP reduces 
3 ectopic lipid accumulation through suppression of lipolysis in adipose tissue and by reducing 
4 de-novo lipogenesis in liver. We have demonstrated for the first time that acetate modulates 
5 mitochondrial function in liver, increasing OXPHOS and ATP production, and in the SAT 
6 increasing thermogenic activity. Our findings show that acetate has the potential to be a 
7 novel and effective treatment for obesity and fatty liver disease.
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5 Figure 1. Acetate Reduces Whole Body and Liver Lipid Accumulation 
6 Change in whole body lipid content in HFD (a) and NFD (b) fed mice treated with and 
7 without LITA (n=24). Lean mass of control and LITA treated mice fed with HFD (c) and NFD 
8 (d) (n=8). Change in liver lipid content in HFD (e) and NFD (f) fed mice treated with and 
9 without LITA (n=24). All data are shown as mean ± SD, *p<0.05. 
10
11 Figure 2. Acetate Improves Liver Function and Inflammation 
12 (a) Serum concentration of ALT, AST and ALP of control and LITA treated mice under HFD 
13 feeding (n=12). (b) Inflammatory markers TNF-α and IL-6 of control and LITA treated mice 
14 under HFD feeding (n=18). (c) Fold change in LITA TNF-α expression compared to control 
15 in liver and SAT of mice fed with HFD. Dotted line represents control (n=6). (d) Serum 
16 concentration of ALT, AST and ALP of control and LITA treated mice under NFD feeding 
17 (n=6). (e) Fold change in LITA TNF-α expression from control (represented by dotted line) in 
18 liver of mice fed with NFD (n=6). (f) Serum concentration of peptides of control and LITA 
19 administered mice on NFD diet (n=18). (g) Concentration of other serum peptides of mice 
20 fed with HFD (n=18). All data are shown as mean ± SD, #p<0.1, *p<0.05, **p<0.01 and 
21 ***p<0.001. 
22
23 Figure 3. Glucose Metabolism is Altered by Acetate 
24 (a) Blood glucose concentration of control and LITA administered mice fed with NFD after 
25 i.p. glucose administration. (b) Area under the curve of blood glucose concentrations (n=10). 
19
1 (c) Blood glucose concentration of control and LITA administered mice fed with HFD after 
2 i.p. glucose administration. (d) Area under the curve of blood glucose concentrations (n=10). 
3 (e) Fed and fasted blood glucose (n=24 and 18, respectively) and serum insulin 
4 concentrations (n=6 and 8, respectively) for control and LITA administered mice fed with 
5 NFD. (f) Fed and fasted blood glucose (n=36 and 22, respectively) and serum insulin 
6 concentrations (n=18 and 12, respectively) for control and LITA administered mice fed with 
7 HFD. (g) HOMA-IR for control and LITA administered mice fed with NFD (n=6) and HFD 
8 (n=12). (h) Fold change in LITA gene expression compared to control (represented by 
9 dotted line) in liver of mice fed with HFD (n=6).  All data are shown as mean ± SD, *p<0.05 
10 and **p<0.01.
11
12 Figure 4. Acetate Suppresses SAT Lipolysis and Liver de-novo Lipogenesis 
13 (a) Fold change in LITA mRNA expression of genes involved in lipolysis compared to control 
14 (represented by dotted line) in SAT of mice fed with HFD (n=6). (b) Serum lipid 
15 concentrations of control and LITA administered mice fed with HFD (n=11). (c) Fold change 
16 in LITA mRNA expression of genes involved in fatty acid synthesis, β-oxidation and VLDL 
17 metabolism compared to control (represented by dotted line) in liver of mice fed with HFD 
18 (n=6). All data are shown as mean ± SD, *p<0.05, **p<0.01 and ***p<0.001.
19
20 Figure 5. Acetate Improves Liver Mitochondrial Function 
21 (a) Representative TEM image of liver at 1200x magnification used to count the number of 
22 mitochondria. (b) Number of mitochondria per image of control and LITA administered mice 
23 fed on HFD (n=4). (c) A representative TEM image at 4800x magnification used to calculate 
24 the number cristae per mitochondrion. (d) Number of cristae per mitochondrion of control 
25 and LITA administered mice fed on HFD (n=3). (e) Fold change in LITA mRNA expression of 
26 genes involved in mitochondrial function compared to control (represented by dotted line) in 
27 liver of mice fed with HFD (n=6). (f) Change in protein expression of OXPHOS complexes of 
20
1 mitochondria isolated from the liver of control and LITA administered mice (n=5). (g) 
2 Mitochondrial function, assessed by OCR, of THLE-2 cells treated with acetate 6 times, 
3 normalized to untreated cells (represented by dotted line, n=4). (h) Representative WB 
4 image showing complexes I-V. All data are shown as mean ± SD, #p<0.1, *p<0.05, **p<0.01 
5 and ***p<0.001.
6
7 Figure 6. Acetate Increases Heat Dissipation through Browning of SAT 
8 Heat produced measured by CLAMS of control and LITA administered mice fed with HFD 
9 shown as time course (a) and sum of light and dark phases (b) (n=8). Heat produced 
10 measured by CLAMS of control and LITA administered mice fed with NFD shown as time 
11 course (c) and sum of light and dark phases (d) (n=8). Fold change in LITA mRNA 
12 expression of BAT signature genes compared to control (represented by dotted line) in SAT 
13 of mice fed with HFD (n=6) (e) of mice fed with NFD (n=6) (f) and in BAT of mice fed with 
14 HFD (g). (h) Weight of BAT tissue dissected from the NFD and HFD fed mice (n=12). All 
15 data are shown as mean ± SD except from (a) and (c) which are shown as mean ± SEM, 
16 *p<0.05, **p<0.01 and ***p<0.001. 
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